NasdaqGM:CSTLHealthcare
Should Expert Endorsement of DecisionDx-Melanoma’s Prognostic Value Require Action From Castle Biosciences (CSTL) Investors?
Earlier this month, Castle Biosciences announced that an independent expert consensus panel published a paper endorsing its DecisionDx-Melanoma test as a clinically validated tool that adds prognostic value beyond standard staging in cutaneous melanoma care.
The panel’s unanimous agreement, based on 26 studies covering more than 7,500 patients, positions DecisionDx-Melanoma as part of best-practice risk stratification and treatment planning, while separate meta-analysis data support...